Greece-based pharmaceutical manufacturer Demo on Tuesday announced an ambitious investment plan of 356 million euros up until 2027, mainly aiming at a further expansion into the production of raw materials, production of final products, as R&D and biotechnology.
According to CEO Dimitris Demos, the capital investment plan envisions an expansion of the main Demo plant due north of Athens, at the Kryoneri site; three new raw materials units and four pharmaceutical production units in Tripoli, Arcadia prefecture, southern Greece; a new R&D lab in the northern city of Thessaloniki and high-profile new unit for the production of monoclonal antibodies along with a “BioAcademy” in the greater Athens area.
Μια βραδιά στο κέντρο της πόλης γεμάτη τραγούδια, ιστορίες και μουσικές που έχουν καθιερώσει την Μαρία Παπαγεωργίου ως μία από τις σημαντικότερες ερμηνεύτριες και δημιουργούς της γενιάς της.